An experimental CAR T-cell therapy has driven advanced, chemotherapy-resistant liver cancer into a durable complete remission in a 3-year-old boy, according to a medical report published in the New England Journal of Medicine. The toddler, treated through an ongoing phase 1 trial at Baylor College of Medicine and Texas Children’s Hospital, remains cancer-free a year after receiving outpatient infusions without systemic toxicity.
CAR T-Cell Therapy Engineered for Solid Tumors
Traditional chimeric antigen receptor T-cell therapies have transformed the treatment landscape for blood cancers like leukemia and lymphoma, with response rates ranging from 25% to 90%. However, solid tumors have historically resisted these therapies due to complex antigen presentations and robust immune system defenses, according to clinical findings. To bypass these hurdles, researchers in the CARE study designed a specialized treatment targeting glypican-3 (GPC3), a cell-surface protein heavily expressed on cancerous liver cells but sparse on healthy mature tissue, as detailed by Baylor College of Medicine.
The experimental cells were further engineered to co-express interleukin-15 and interleukin-21, two immune signaling proteins designed to boost T-cell survival and tumor-fighting potency. Researchers also included a built-in safety switch gene, allowing clinicians to eliminate the modified cells using an intravenous drug if dangerous side effects emerged. Unlike standard treatments that often require inpatient hospital stays and trigger severe immune reactions such as cytokine release syndrome, this novel approach was delivered entirely in an outpatient setting.
From Chemotherapy Resistance to Complete Remission
The young patient diagnosed with hepatoblastoma—the most common malignant liver tumor in children—faced a poor prognosis after frontline therapies failed. At diagnosis, his primary liver tumor measured 11.2 by 9.6 by 7.1 centimeters, with metastatic spread to his lungs and bones. Despite undergoing surgery, three lines of chemotherapy, and two separate lung operations to clear metastases, the cancer returned with a new lung tumor.
Enrolled in the phase 1 trial, the boy received two outpatient infusions of his own genetically modified T-cells spaced eight weeks apart. Following the initial infusion, computed tomography scans showed shrinking tumors and declining levels of alpha-fetoprotein, a tumor marker associated with hepatoblastoma. After the second dose, imaging revealed no detectable disease, leaving only residual scarring. At the 12-month evaluation, the patient showed no evidence of disease and experienced no dose-limiting toxicities, according to study data.
Did you know? Hepatoblastoma is the most common form of pediatric liver cancer, yet solid tumors have long evaded standard CAR T-cell therapies that typically excel against blood cancers.
Clinical Implications and Future Trial Directions
“This case shows that a durable complete remission in a patient with a chemotherapy-resistant solid tumor can be achieved entirely in the outpatient setting without systemic toxic effects,” study authors wrote in the New England Journal of Medicine. Co-author Andras Heczey, a pediatric oncologist formerly with Baylor College of Medicine and now at the University of Washington School of Medicine and Seattle Children’s Hospital, noted that the findings offer evidence that these novel CAR T cells provide a safe and effective modality for hepatoblastoma.
While the dramatic turnaround offers a promising proof of concept, researchers emphasize that this represents a single patient in an early-stage safety trial. The broader CARE study aims to enroll between 18 and 30 patients with similar liver cancer cases, with the primary phase scheduled for completion by next summer, according to Baylor College of Medicine records.
Frequently Asked Questions
What is hepatoblastoma?
Hepatoblastoma is the most common malignant liver tumor diagnosed in children, typically carrying a poor prognosis once frontline surgical and chemotherapy options fail.
How does GPC3 CAR T therapy differ from standard CAR T?
While standard CAR T treatments target blood cancers and frequently cause severe inpatient side effects like cytokine release syndrome, the experimental GPC3-targeted cells are armed with interleukin-15 and interleukin-21 to fight solid tumors safely in an outpatient setting.
Is this treatment widely available?
No. The therapy remains strictly investigational, lacks FDA approval, and is currently accessible only to participants enrolled in specific clinical trials like the ongoing CARE study.
Explore More Medical Breakthroughs
Worth a look